Johnson & Johnson Unveils Promising New Rybrevant Treatment at ASCO Annual Meeting

Johnson & Johnson Unveils Promising New Rybrevant Treatment at ASCO Annual Meeting

Nikolai Ivanov
2 min read

Johnson & Johnson Presents Promising Results for Subcutaneous Rybrevant at ASCO Annual Meeting

At the American Society of Clinical Oncology (ASCO) Annual Meeting, Johnson & Johnson unveiled encouraging data on their subcutaneous version of Rybrevant, a treatment for metastatic non-small cell lung cancer. The newly formulated subcutaneous Rybrevant, in combination with lazertinib, demonstrated improved survival rates and reduced infusion-related reactions compared to the intravenous version. Specifically, the subcutaneous (SC) treatment exhibited a median progression-free survival of 6.1 months, a 12-month survival rate of 65%, and a reduced 13% incidence of infusion-related reactions, making it a significant advancement in patient care. An additional advantage is its ease of administration and better tolerability. Johnson & Johnson is actively seeking regulatory approval for this groundbreaking treatment option, which is anticipated to generate $4 billion in sales by 2030, with over half coming from this combination regimen.

Key Takeaways

  • The projected sales of Rybrevant are estimated to reach $4 billion by 2030.
  • The subcutaneous Rybrevant displayed a longer median duration of response at 11.2 months compared to 8.3 months for the intravenous option.
  • The subcutaneous formulation reduced infusion-related reactions to 13%, a stark contrast to the 66% associated with the intravenous option.
  • The median progression-free survival for subcutaneous Rybrevant was 6.1 months, whereas it was 4.3 months for the intravenous variant.
  • Johnson & Johnson is preparing to submit regulatory applications for the subcutaneous Rybrevant in the US and other markets.


Johnson & Johnson's subcutaneous Rybrevant, in partnership with lazertinib, represents a monumental progression in the treatment of metastatic non-small cell lung cancer. This innovation not only offers enhanced survival rates and decreased side effects but also has the potential to reshape treatment protocols, benefitting both patients and the company economically. With projections of $4 billion in sales by 2030, J&J's regulatory approval for this new treatment alternative may set a new standard, significantly impacting healthcare providers and competitors in the oncology market. This development could pave the way for more patient-friendly cancer therapies and substantial revenue growth for J&J.

Did You Know?

  • Subcutaneous (SC) Administration: This method involves injecting a drug or medication into the fatty layer just beneath the skin, providing ease of use, reduced risk of infection, and faster absorption rates compared to oral administration. In the context of Rybrevant, the subcutaneous administration offers a more convenient and potentially safer alternative to intravenous (IV) infusion, reducing the incidence of infusion-related reactions and improving patient comfort.
  • Progression-Free Survival (PFS): PFS measures the length of time a patient lives with a disease without it worsening during and after treatment. A longer PFS suggests that the treatment is effectively controlling the disease, delaying its progression. The subcutaneous Rybrevant demonstrated a PFS of 6.1 months, superior to the intravenous version and indicating better disease control.
  • Lazertinib: This third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor is highly effective against tumors with EGFR mutations, including the T790M resistance mutation common in NSCLC. When combined with Rybrevant in the subcutaneous formulation, lazertinib enhances the treatment's efficacy, targeting EGFR mutations and improving survival rates while reducing disease progression.

You May Also Like

This article is submitted by our user under the News Submission Rules and Guidelines. The cover photo is computer generated art for illustrative purposes only; not indicative of factual content. If you believe this article infringes upon copyright rights, please do not hesitate to report it by sending an email to us. Your vigilance and cooperation are invaluable in helping us maintain a respectful and legally compliant community.

Subscribe to our Newsletter

Get the latest in enterprise business and tech with exclusive peeks at our new offerings